| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
We established platinum drug-resistant lung cancer cell lines and found that the intracellular platinum concentration was decreased concomitantly with decreased organic cation transporter 6 (OCT6) expression in the platinum-drug resistant cell lines. The present findings indicate that OCT6 is directly involved in platinum drug resistance by mediating platinum drug uptake in cancer cells. Then we focused on a functional single nucleotide polymorphism (SNP) of OCT6. We retrospectively examined the relationship between the efficacy of cisplatin and OCT6 SNP in non-small lung cancer patients. We found that progression free survival was significantly different depending on OCT6 SNP. This OCT6 SNP has shown influenced on doxorubicin pharmacokinetics, therefore we are now going to investigate the influence of OCT6 SNP for another anthracycline derivative, amrubicin.
|
